Neuroprotective agents in schizophrenia and affective disorders (Q36458436)

14 August 2017

1 reference

title

Neuroprotective agents in schizophrenia and affective disorders (English)

1 reference

14 August 2017

0 references

Michael Krebs

1

1 reference

14 August 2017

Karolina Leopold

series ordinal

2

1 reference

14 August 2017

Axel Hinzpeter

series ordinal

3

1 reference

14 August 2017

Martin Schaefer

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

7

1 reference

14 August 2017

837-848

1 reference

Acetylcholinesterase inhibitors: novel activities of old molecules.

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Anatomical MRI abnormalities in bipolar disorder: do they exist and do they progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neurodegeneration: what is it and where are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Developmental cell death: morphological diversity and multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroprotection--what does it mean?--What means do we have?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Implications for neuroprotective treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Ventricular enlargement in poor-outcome schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Pathobiology of ischaemic stroke: an integrated view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

SOD, oxidative stress and human pathologies: a brief history and a future vision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Metabotropic glutamate receptors and neuronal degenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Functional neurogenesis in the adult hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Atypical neuroleptics stimulate neurogenesis in adult rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+‐induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Haloperidol treatment decreases nerve growth factor levels in the hypothalamus of adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Antipsychotic drug effects on brain morphology in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Acute and maintenance treatment with mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Antiepileptic drugs in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Topiramate prevents excitotoxic damage in the newborn rodent brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Levetiracetam in the treatment of rapid cycling bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Antidepressants and neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Glutamatergic mechanisms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

D-alanine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Modafinil prevents glutamate cytotoxicity in cultured cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Memantine and catatonic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Glutamate inhibition in MS: the neuroprotective properties of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

COX-2 inhibitors as adjunctive therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Erythropoietin: novel approaches to neuroprotection in human brain disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Efficacy and tolerability of low-dose donepezil in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

The effect of galantamine added to clozapine on cognition of five patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Galantamine for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Cerebral ventricular change over the first 10 years after the onset of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Enhancement of hippocampal neurogenesis by lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Pharmacology of N-methyl-D-aspartate-induced brain injury in an in vivo perinatal rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

Development of subtle psychotic symptoms with memantine: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.7.837

21 January 2018

Identifiers

DOI

10.1517/14656566.7.7.837

1 reference

14 August 2017

1 reference